Numab
Sebastian Wolniak is a skilled researcher with a robust background in the life sciences, currently serving as a Research Associate at Numab Therapeutics AG since April 2022. Prior experience includes roles as a Consultant at ALTEN Switzerland AG and Quality Control Analyst at Novartis from August 2020 to April 2022, as well as an internship and research assistant position at Universität Konstanz from November 2019 to July 2020. Earlier experience includes working as a researcher at Philipps-Universität Marburg during an external master thesis from August 2017 to July 2018 and as an intern at Karolinska Institutet from October 2015 to March 2016. Sebastian holds a Master of Science degree in Biology from Ruhr University Bochum, earned in 2018, and a Bachelor of Science degree in Biology from the same institution, completed in 2016.
This person is not in any offices
Numab
Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, they are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies.